Contents
Academic literature on the topic 'Blepharitis, complications'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Blepharitis, complications.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Blepharitis, complications"
1
Rachdan, Diyaa, M. Saad Khan, Asim Ali, and Kamiar Mireskandari. "Severe corneal complications in children with blepharitis." Journal of American Association for Pediatric Ophthalmology and Strabismus 19, no. 4 (August 2015): e30-e31. http://dx.doi.org/10.1016/j.jaapos.2015.07.083.
Full text
2
Drozdova, E. A., and E. V. Mikhailova. "Individual Approach to the Treatment of Complicated Forms of Blepharitis: from Theory to Practice." Ophthalmology in Russia 17, no. 4 (December 27, 2020): 830–37. http://dx.doi.org/10.18008/1816-5095-2020-4-830-837.
Full textAbstract:
High prevalence of blepharitis, multifactorial etiology and chronic course with the possibility of serious complications, including conjunctivitis, multiple chalazions, keratitis, dry eye syndrome — cause significant difficulties in the treatment of this disease. Prescribing treatment of the process only in case of exacerbation with the use of even modern antimicrobial and anti-inflammatory drugs gives only a short-term effect.The aim is to present the clinical features of the blepharitis of different localization and the choice of the optimal treatment algorithm on the example of specific clinical cases. The article presents current data on the classification, etiology and mechanism of blepharitis development. Based on a detailed description of two clinical cases of blepharitis, the features of the clinical course, the range of necessary examinations and consultations of specialists are presented. The first case describes blepharitis associated with the severe rosacea in a teenager with a typical complication in the form of rosacea — keratitis. The second case is devoted to the features of the posterior blepharitis clinical course with meibomian gland dysfunction, complicated by multiple chalazions. The article explains in detail the stages of prescribing various medications, including eyelid hygiene, antibacterial, anti-inflammatory therapy and artificial tears, discusses possible side effects of the therapy and ways to restore the eye surface.Conclusion. The basis of blepharitis treatment is regular three-component eyelid hygiene. In case of exacerbation it is advisable to prescribe antibacterial and anti-inflammatory drugs, taking into account the sensitivity and ability to destroy microbial biofilms. In order to increase patient adherence to treatment, the choice of hygiene products and moisturizing drops should take into account the tolerability of the drug and the convenience of its use.
3
Ahmad, Adnan. "Ophthalmic Complications Associated with Atopic Dermatitis: A Review." Journal of Islamic International Medical College 17, no. 4 (December 29, 2022): 286–91. http://dx.doi.org/10.57234/1396.
Full textAbstract:
Atopic dermatitis (AD) is a long-lasting dermatological disease that is associated with ophthalmic complications in the long run. Those having AD are more likely at risk of developing comorbidities in eye as compared to normal persons. This review encompasses the clinical manifestations, pathophysiology and treatment of common ophthalmic complications presented with AD i.e., blepharitis, kerato-conjunctivitis, corneal ectasias, glaucomatous eyes, lens opacification, detachment of retina, herpetic eye disease (HED) and dupilumab associated eye toxicities. It is necessary for dermatology colleagues to be vigilant enough not to miss ophthalmic problems associated with AD, as an early detection and management can save the vision.
4
Puri, Sonam, Jitesh Joshi, Olga Derman, Noah Kornblum, Amit Verma, Ira Braunschweig, and Ramakrishna Battini. "Ocular Complications of Bortezomib Therapy in Multiple Myeloma." Blood 124, no. 21 (December 6, 2014): 5743. http://dx.doi.org/10.1182/blood.v124.21.5743.5743.
Full textAbstract:
Abstract Introduction: Bortezomib (Velcade¨; V), a proteasome inhibitor, is currently FDA (Food and Drug Administration) approved for the treatment of multiple myeloma (MM) and relapsed mantle cell lymphoma. Common side effects reported with its use include thrombocytopenia, fatigue, peripheral neuropathy and neutropenia. Ocular complications associated with bortezomib are less well described. We describe 6 patients with multiple myeloma who developed meibomitis, multiple chalazions and blepharitis after treatment with bortezomib containing regimens, resulting in delay and in some cases termination of the therapy. Methods: We reviewed the charts of forty patients who received induction chemotherapy for multiple myeloma between June 2013-June 2014 at Montefiore Medical Center, New York. Charts were reviewed for data pertaining to demographics, chemotherapy regimen and schedule as well as follow up of ocular symptoms. Results: Six of these forty (15%) patients complained about bilateral eye soreness, itching and redness. They did not have any evidence of viral or upper respiratory infections. Ophthalmology evaluation showed blepharitis, meibomitis and multiple chalazion. Majority of the patients were 60 years or greater, with 50% African-Americans. Half of the cases had stage 3 MM with a median duration of chemotherapy 8 weeks prior to onset of ocular symptoms. 4 of these 6 patients received VCD regimen (Bortezomib via subcutaneous route and Cyclophosphamide/ Dexamethasone as tablets) while the remaining 2 patients received VD and VCD-R (addition of Lenalidomide) via intravenous and subcutaneous route respectively. Ocular symptoms led to a 1-3 week delay in the next cycle of chemotherapy. These symptoms promptly responded to withdrawal of chemotherapy and other conservative measures. Chemotherapy was resumed in 4 out of 6 patients, with recurrence of chalazion in two patients within 3 weeks of starting Bortezomib. Conclusions: Ocular symptoms are commonly seen but rarely reported with bortezomib therapy. They can adversely affect patient's quality of life as well as lead to interruption in chemotherapy. Although these symptoms respond well to withdrawal of chemotherapy and conservative measures, the rate of recurrence is high once bortezomib is resumed. Awareness of these complications and early intervention can potentially avoid treatment delay. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare.
5
Arrico, L., A. Abbouda, I. Abicca, and R. Malagola. "Ocular Complications in Cutaneous Lupus Erythematosus: A Systematic Review with a Meta-Analysis of Reported Cases." Journal of Ophthalmology 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/254260.
Full textAbstract:
Ocular complications associated with cutaneous lupus erythematosus (CLE) are less studied compared with those ones associated with systemic lupus erythematosus (SLE). The main ocular sites involved in patients affected by discoid lupus erythematosus (DLE) are eyelids followed by orbit and periorbit, the least being cornea. The most common complications are blepharitis usually affecting the lower lid and associated with some type of lid lesion such as plaque or erythematosus patches and madarosis. Few cases with LE profundus (LEP) and ocular complications are reported, but they are associated with orbital inflammatory syndrome and severe complications. The main treatment prescribed is hydroxychloroquine with a dose of 200 mg twice a day for 6 to 8 weeks. Corticosteroids are also used. Intervals between the correct diagnosis and the beginning of the ocular symptoms are commonly delayed. Ophthalmologist should be aware of the ocular manifestation of this autoimmune disease.
6
Nesterov, A. P. "Diabetic involvement of the organ of vision." Problems of Endocrinology 43, no. 3 (September 18, 2019): 16–19. http://dx.doi.org/10.14341/probl10388.
Full textAbstract:
Diabetic involvements of the organ of vision may be divided into extraocular and ocular. The first group includes xanthelasma and eczemas of the eyelids, hordeolum, chalasion, blepharitis, acute and chronic conjunctivitis, conjunctival angiopathies, and pareses of the extraocular muscles. The second group in- cludes*iridal dystrophy, anterior uveitis, cataract, glaucoma, asteroid hyalosis, lipemia rctinalis, and diabetic retinopathy with its complications (hemophthalmia, detachment of the retina, and neovascu- lar glaucoma). Diabetic retinopathy is a late complication of diabetes mellitus. The author discusses the epidemiology of this condition, its pathophysiological and clinical features, classification, contribution of local factors to its pathogenesis, and possibilities of treatment and prevention of the disease. He emphasizes the leading role of optimal correction of carbohydrate metabolism as a means preventing diabetic retinopathy and of timely laser photocoagulation of the retina in its treatment.
7
Manabe, Yusuke, Akira Sawada, and Kiyofumi Mochizuki. "Corneal sterile infiltration induced by topical use of ocular hypotensive agent." European Journal of Ophthalmology 30, no. 5 (May 17, 2019): NP23—NP25. http://dx.doi.org/10.1177/1120672119850080.
Full textAbstract:
Purpose: To report two cases with corneal sterile infiltration presumably due to topical ocular hypotensive agent. Method: Case report. Results: Case 1: A 65-year-old man presented with corneal opacity and neovascularization in his left eye. A diagnosis of glaucoma was made 2 years previously, and anti-glaucoma agents were prescribed (brimonidine tartrate, ripasudil hydrochloride hydrate, and brinzolamide) for both eyes. Case 2: A 75-year-old woman noticed corneal opacity in the left eye. A diagnosis of glaucoma was made 35 years previously, and anti-glaucoma agents were prescribed (brimonidine tartrate, 1% dorzolamide, and bimatoprost) for both eyes. In both cases, ocular examination revealed follicular conjunctivitis and blepharitis in both eyes, and corneal sterile infiltration with neovascularization in the left eyes. The three topical drugs were discontinued and replaced with 0.1% fluorometholone. Both the blepharitis and corneal sterile infiltration improved thereafter, although corneal opacity remained across the stromal layer. Conclusion: We encountered two cases of corneal and conjunctival complications that were suspected as side effects after brimonidine eye drop use. Special care should be taken to observe the condition of ocular surface when topical brimonidine is administered.
8
Saraswati Surya, Putu Ayu Adindhya, and Ni Nyoman Sunariasih. "Blepharoconjunctivitis as Manifestation of Stevens-Johnson syndrome." Medical and Health Science Journal 5, no. 2 (August 31, 2021): 26–32. http://dx.doi.org/10.33086/mhsj.v5i2.2189.
Full textAbstract:
Background: Stevens Johnson syndrome (SJS) is a collection of acute and life threatening skin symptoms caused by an allergic drug reaction. SJS also attacks the other mucous membranes, one of which is the eye. SJS is a rare case. The initial complaint of SJS is the eruption on the skin in the form of redness followed by blisters and attacking other mucous membranes. The ocular manifestations of SJS are conjunctivitis, corneal erosion, corneal ulcers, and blepharitis. Methods: Treatment of SJS’s ocular manifestation is administration of drugs and surgical intervention. Administration of drugs that often done in the acute phase is antibiotic eye drops with steroids to prevent complications. Complications that can occur include symblepharon, districhiasis, and keratitis. This complication can cause a sharp decrease in vision. Results: This case report discusses a 68 year old male patient with blisters all over his body accompanied by swelling in both eyes, redness in both eyes, and difficult to open eyes. Patients with history of taking the new drug a month ago. No history of drug allergy. The patient suffered from hypertension, non-hemorrhagic stroke, and epilepsy with irregular treatment. Patient was performed a fluorescein test. In this case, the patient is given antibiotic ointment and artificial tears with steroids. In this case there were no complications. Conclusion: The ocular manifestations of SJS if handled quickly and properly can prevent long-term complications.
9
Suvajac, Gordana. "Soft-contact-lenses-induced complications." Vojnosanitetski pregled 65, no. 1 (2008): 15–20. http://dx.doi.org/10.2298/vsp0801015s.
Full textAbstract:
Background/Aim. Soft contact lenses occupy significant place in ophthalmology, both in the correction of refraction anomalies and in the treatment of many eye diseases. The number of patients that wear soft contact lenses for the purpose of correcting ametropia is constantly increasing. Due to the increasing number of wearers, the percentage of complications that can lead to serious eye damage and serious vision loss is also increasing. The aim of this study was to point out the most common complications related to soft contact lens use. Methods. In the period from 1995?2004 this prospective study included 510 patients wearing soft contact lenses for correcting ametropia. None of the patients wore contact lenses before and none suffered from any system or local diseases that could affected the development of eventual complications. The study took seven years with the patients who wore conventional lenses and three years with those who wore replacement contact lenses. All the necessary ophthalmologic examinations were done (visual acuity, refractokeratometry, the quantity of tear film, biomicroscopic examination of anterior eye segment). All the complications were filmed by video camera. Results. Of all the patients, 19 had blepharitis, 73 suffered from ?dry eye?, 57 had conjunctival hyperemia, 12 had conjunctivitis, 34 had gigantopapillary conjunctivitis (GPC), 93 had punctiform epitheliopathy, 20 had corneal infiltration, one patient had keratitis, 91 had corneal vascularisation, and 95 patients had corneal deposits. Conclusion. Both the type and frequency of complications related to soft contact lens use in our group of patients, proved to be significant. Some of this complications (keratitis) can significantly damage vision and lead to loss of vision and sometimes can require operative treatment.
10
Bozkurt, B., M. T. ÍRkeç, N. Atakan, M. Orhan, and P. Ö. Geyik. "Lacrimal Function and Ocular Complications in Patients Treated with Systemic Isotretinoin." European Journal of Ophthalmology 12, no. 3 (January 2002): 173–76. http://dx.doi.org/10.1177/112067210201200316.
Full textAbstract:
Purpose To evaluate the effect on lacrimal function and ocular complications in patients with severe acne vulgaris during systemic treatment with 13- cis -retinoic acid (isotretinoin). Methods Forty patients with acne vulgaris were treated with systemic isotretinoin at dosages of 0.5-1 mg/kg per day for two months. Full ophthalmologic examination, Schirmer / test, fluorescein break-up (BUT) and microbiological investigations of the conjunctival flora were done before, during the second month and at least one month after the end of the treatment. Results The average Schirmer values before and after the treatment were 21.6 mm/5 minutes (SD ± 7.01) and 18.48 mm/5 minutes (SD ± 7.87) respectively. After the treatment BUT was less than 10 seconds in 50% of the patients and 55% had blepharitis. Subjective symptoms like dryness, itching and contact lens intolerance occurred in 42.5% and colonization of the conjunctiva by Staphylococcus aureus increased significantly during treatment (p = 0.031). All abnormal findings disappeared one month after the cessation of treatment. Discussion Isotretinoin causes signs and symptoms of dry eye, probably by reducing meibomian gland function, but ocular complications are generally not serious when low doses are used for a limited time, and are reversible after discontinuation.
Books on the topic "Blepharitis, complications"
1
Goyal, Saurabh, Allon Barsam, and Stephen Tuft. External eye disease. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199237593.003.0001.
Full textAbstract:
This chapter covers corneal and conjunctival basic science, before covering clinical skills (history taking for anterior segment disease and examination of the anterior segment). The chapter then covers blepharitis, staphylococcal hypersensitivity disorders, dry eye disease, conjunctivitis, cicatrizing conjunctival disease, conjunctival degeneration, conjunctival neoplasia, corneal degeneration, infectious keratitis, interstitial keratitis, peripheral ulcerative keratitis, metabolic and drug-induced keratopathies, corneal dystrophies, contact lenses, corneal ectasia, keratoplasty, complications of keratoplasty and graft rejection, anterior uveal tumours, anterior segment trauma, chemical injury, and refractive surgery. Practical skills are then covered, including corneal glue, removal of corneal sutures, removal of corneal foreign bodies, corneal topography, and corneal pachymetry. The chapter concludes with three case-based discussions, on chemical injury, Herpes zoster keratitis, and bacterial keratitis.
Book chapters on the topic "Blepharitis, complications"
1
Seal, David, and Linda Ficker. "Immunology and Therapy of Marginal Ulceration as a Complication of Chronic Blepharitis Due to S. aureus." In Advances in Corneal Research, 19–25. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5389-2_2.
Full text
2
Robert, Copeland. "Chapter-039 Blepharitis and Meibomian Gland Dysfunction." In Contemporary Surgical Management of Fractures and Complications (2 Volumes), 482–96. Jaypee Brothers Medical Publishers (P) Ltd., 2013. http://dx.doi.org/10.5005/jp/books/11776_39.
Full text